Skip to main content

Advertisement

SpringerLink
Log in

Full-Course Oral Levofloxacin for Treatment of Hospitalized Patients with Community-Acquired Pneumonia

  • Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Most guidelines for the management of hospitalized patients with community-acquired pneumonia (CAP) recommend commencing therapy with intravenous antibiotics, primarily because of concern about absorption of oral antibiotics in acutely ill patients. However, patients who respond are rapidly switched to oral therapy, which has been shown to reduce costs and to shorten the length of stay. The aim of the present study was to determine whether a full course of oral antibiotics is as efficacious and as safe as intravenous-to-oral sequential antibiotic therapy for the treatment of hospitalized, non-ICU patients with CAP. In an open-labelled, controlled study, 129 hospitalized patients with CAP were randomly assigned in a 2:1 ratio to receive either a full course of oral levofloxacin (500 mg q12 h) or an intravenous-to-oral sequential therapy consisting of intravenous ceftriaxone (2 g q24 h) with or without clarithromycin (500 mg q12 h) followed by an oral antibiotic (a beta-lactam agent in the majority of patients). The primary study endpoint was the resolution of CAP; secondary endpoints included length of stay and overall mortality. CAP resolved in 72 of 79 (91.1%) patients in the levofloxacin group and in 34 of 37 (91.9%) patients in the intravenous-to-oral sequential therapy group (difference, −0.8%, 95%CI, −11.6–10.0). Median length of stay was 8 days (range, 2–74 days) in the levofloxacin group and 10 days (range, 3–29 days) in the intravenous-to-oral sequential therapy group (P=0.28). Day 30 mortality rates were 1.3% (1 of 79) and 8.1% (3 of 37), respectively (difference, −6.8%, 95%CI, −16.0–2.3). Full-course oral levofloxacin is as efficacious and as safe as standard intravenous-to-oral sequential antibiotic therapy for the treatment of hospitalized patients with CAP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anonymous (2001) BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 56 (Suppl 4):1–64

    Article  PubMed  Google Scholar 

  2. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ (2000) Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 31:347–382

    PubMed  Google Scholar 

  3. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH (2000) Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 31:383–421

    CAS  PubMed  Google Scholar 

  4. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730–1754

    PubMed  Google Scholar 

  5. Hirata-Dulas CA, Stein DJ, Guay DR, Gruninger RP, Peterson PK (1991) A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections. J Am Geriatr Soc 39:979–985

    Google Scholar 

  6. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ (1995) Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 155:1273–1276

    Article  CAS  PubMed  Google Scholar 

  7. Hendrickson JR, North DS (1995) Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 29:561–565

    CAS  PubMed  Google Scholar 

  8. Chan R, Hemeryck L, O’Regan M, Clancy L, Feely J (1995) Oral versus intravenous antibiotics for community-acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. Br Med J 310:1360–1362

    CAS  Google Scholar 

  9. Oh HM, Ng AW, Lee SK (1996) Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Singapore Med J 37:255–257

    CAS  PubMed  Google Scholar 

  10. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG (1996) A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 110:965–971

    CAS  PubMed  Google Scholar 

  11. Ramirez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, Newman D, Burke J, Mushtaq M, Huang A (1999) Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 159:2449–2454

    Article  CAS  PubMed  Google Scholar 

  12. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG (2000) A controlled trial of a critical pathway for treatment of community-acquired pneumonia. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 283:749–755

    Article  CAS  PubMed  Google Scholar 

  13. Vogel F (2002) Intravenous/oral sequential therapy in patients hospitalised with community-acquired pneumonia: which patients, when and what agents? Drugs 62:309–317

    CAS  PubMed  Google Scholar 

  14. File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A (1997) A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 41:1965–1972

    CAS  PubMed  Google Scholar 

  15. Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E (1998) A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 30:397–404

    Article  CAS  PubMed  Google Scholar 

  16. Work Group for Practice Guidelines for Community-Acquired Pneumonia (1999) Diagnostic and treatment of community-acquired pneumonia in the adult. Recommendations for clinical practice. Rev Med Suisse Romande 119:403–427

    PubMed  Google Scholar 

  17. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

    CAS  PubMed  Google Scholar 

  18. Wong LK, Barry AL, Horgan SM (1982) Comparison of six different criteria for judging the acceptability of sputum specimens. J Clin Microbiol 16:627–631

    CAS  PubMed  Google Scholar 

  19. Reisner BA, Woods GL, Thomson RB, Larone DH, Garcia LS, Shimizu RY (2002) Specimen processing. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds) Manual of clinical microbiology. ASM Press, Washington DC, pp 64

  20. Jorgensen JH, Turnidge JD, Washington JA (1999) Antibacterial susceptibility tests: dilution and disk diffusion. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds) Manual of clinical microbiology, 7th edn. ASM Press, Washington DC, pp 1526–1543

  21. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250

    PubMed  Google Scholar 

  22. O’Doherty B, Dutchman DA, Pettit R, Maroli A (1997) Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 40 (Suppl A):73–81

    Article  CAS  PubMed  Google Scholar 

  23. Ramirez J, Unowsky J, Talbot GH, Zhang H, Townsend L (1999) Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin Ther 21:103–117

    Article  CAS  PubMed  Google Scholar 

  24. Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, Segev S, Wijnands G (1995) Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J 8:1999–2007

    Article  CAS  PubMed  Google Scholar 

  25. Ortqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C (1996) Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. Chest 110:1499–1506

    CAS  PubMed  Google Scholar 

  26. Tremolieres F, de Kock F, Pluck N, Daniel R (1998) Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 17:447–453

    Article  CAS  PubMed  Google Scholar 

  27. Carbon C, Ariza H, Rabie WJ, Salvarezza CR, Elkharrat D, Rangaraj M, Decosta P (1999) Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mild-to-moderate community acquired pneumonia. Clin Microbiol Infect 5:724–732

    CAS  Google Scholar 

  28. Moola S, Hagberg L, Churchyard GA, Dylewski JS, Sedani S, Staley H (1999) A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. Chest 116:974–983

    Article  CAS  PubMed  Google Scholar 

  29. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J (2001) Oral moxifloxacin vs. high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 119:185–195

    Article  CAS  PubMed  Google Scholar 

  30. Chen DK, McGeer A, de Azavedo JC, Low DE (1999) Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 341:233–239

    Article  CAS  PubMed  Google Scholar 

  31. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, Fleming C, Low DE (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346:747–750

    Article  PubMed  Google Scholar 

  32. Fredlund H, Bodin L, Back E, Holmberg H, Krook A, Rydman H (1987) Antibiotic therapy in pneumonia: a comparative study of parenteral and oral administration of penicillin. Scand J Infect Dis 19:459–466

    CAS  PubMed  Google Scholar 

  33. Zuck P, Rio Y, Ichou F (1990) Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. J Antimicrob Chemother 26 (Suppl E):71–77

    Google Scholar 

  34. Sanders WE Jr, Morris JF, Alessi P, Makris AT, McCloskey RV, Trenholme GM, Iannini P, Bittner MJ (1991) Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with “usual care” in a multicenter clinical trial. Am J Med 91:261–266

    PubMed  Google Scholar 

  35. Bohte R, van’t Wout JW, Lobatto S, Blusse van Oud AA, Boekhout M, Nauta EH, Hermans J, van den Broek PJ (1995) Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 14:182–187

    CAS  PubMed  Google Scholar 

  36. Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, Armengou-Arxe A, Bisbe-Company, Penarroja-Matutano G, Bisbe-Company, Garcia-Bragado F (2001) Efficacy and safety of oral and early-switch therapy for community- acquired pneumonia: a randomized controlled trial. Am J Med 111:367–374

    Article  CAS  PubMed  Google Scholar 

  37. Aubier M, Verster R, Regamey C, Geslin P, Vercken JB (1998) Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group. Clin Infect Dis 26:1312–1320

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank R. Stoianov and A. Sequin for their help in data collection and follow-up of the patients, and M. Paesmans for advice on statistical analyses. This work was supported in part by a research grant from Aventis (Zurich, Switzerland) and by grants from the Swiss National Science Foundation to T.C. (31–066972.01) and to P-Y.B. (81LA-65462). T.C. is recipient of a career award from the Leenaards Foundation. V. E. and O. L. received travel grants from Aventis for the purpose of presenting the results of the present study and those of an unrelated study on osteoporosis.

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, 1011, Lausanne, Switzerland

    V. Erard, P.-Y. Bochud, A. Cometta & T. Calandra

  2. Department of Internal Medicine (Service A), Centre Hospitalier Universitaire Vaudois, 1011, Lausanne, Switzerland

    O. Lamy

  3. Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, 1011, Lausanne, Switzerland

    J. Bille

  4. Service of Medicine, Centre Hospitalier Yverdon-Chamblon, 1400, Yverdon-les-Bains, Switzerland

    A. Cometta

Authors
  1. V. Erard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Lamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P.-Y. Bochud
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Bille
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Cometta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Calandra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Calandra.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erard, V., Lamy, O., Bochud, PY. et al. Full-Course Oral Levofloxacin for Treatment of Hospitalized Patients with Community-Acquired Pneumonia. Eur J Clin Microbiol Infect Dis 23, 82–88 (2004). https://doi.org/10.1007/s10096-003-1060-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-003-1060-x

Keywords

Search

Navigation